Infectious Disease Research Institute
- Assets
- $13.6m
- Revenue
- $13.3m
- Investments
- $0.0
- Employees
- 65
- Location
- Seattle, WA
- Founding
- 02/2007
- Data as of
- 12/2020
- EIN
- 91-1608978
Organization Overview
Infectious Disease Research Institute is located in Seattle, WA. The organization was established in 2007. According to its NTEE Classification (H80) the organization is classified as: Specifically Named Diseases Research, under the broad grouping of Medical Research and related organizations. As of 12/2021, Infectious Disease Research Institute employed 65 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Infectious Disease Research Institute is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2020, Infectious Disease Research Institute generated $13.3m in total revenue. This represents a relatively dramatic decline in revenue. Over the past 6 years, the organization has seen revenues fall by an average of (11.8%) each year. All expenses for the organization totaled $19.8m during the year ending 12/2020. As we would expect to see with falling revenues, expenses have declined by (3.9%) per year over the past 6 years. You can explore the organizations financials more deeply in the financial statements section below.
Since 2016, Infectious Disease Research Institute has awarded 24 individual grants totaling $3,581,247. If you would like to learn more about the grant giving history of this organization, scroll down to the grant profile section of this page.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2020
Describe the Organization's Mission:
Part 3 - Line 1
DEVELOP VACCINES, ADJUVANTS, DIAGNOSTICS & DRUGS TO PREVENT, DETECT & TREAT INFECTIOUS DISEASES OF GLOBAL IMPORTANCE.
Describe the Organization's Program Activity:
Part 3 - Line 4a
VACCINE RESEARCH - IDRI SCIENTISTS ARE DEVELOPING INNOVATIVE TECHNOLOGIES THAT ENABLE VACCINES WHICH ARE HIGHLY EFFECTIVE, DURABLE, AND ACCESSIBLE TO PEOPLE ACROSS THE GLOBE. THESE VACCINES HAVE FEATURES THAT MAKE THEM UNIQUELY SUITED FOR THE PREVENTION OF INFECTIOUS DISEASE (INCLUDING PANDEMICS), CANCER AND ALLERGIC DISEASES, AND CAN ALSO BE USED AS THERAPEUTIC AGENTS. CURRENT TARGETS INCLUDE COVID-19, INFLUENZA, TUBERCULOSIS, HIV, ZIKA, YELLOW FEVER, LEPROSY, LEISHMANIASIS, AND CHIKUNGUNYA. IDRI SCIENTISTS ARE DEVELOPING AND MANUFACTURING NEXT GENERATION VACCINES INCLUDING THOSE BASED ON RNA AND ADJUVANT PROTEIN PLATFORMS TO RESPOND QUICKLY WHEN DISEASE OUTBREAKS OCCUR. IDRI HAS A ROBUST PIPELINE OF NEW VACCINE CANDIDATES WHICH ARE MOVING SUCCESSFULLY THROUGH EARLY CLINICAL TRIALS.
MANUFACTURING - IDRI HAS CREATED MANUFACTURING CAPABILITIES THAT ALLOW RAPID SCALE-UP AND PRODUCTION OF VACCINES FOR USE IN PHASE 1 AND PHASE 2 CLINICAL TRIALS AND COMPLETES IDRI'S UNIQUE VACCINE DISCOVERY-DEVELOPMENT PROCESS. WHEN IDRI SCIENTISTS IDENTIFY A VACCINE CANDIDATE IN THE LABORATORY, THIS MANUFACTURING CAPABILITY ENABLES THEM TO APPLY THAT DISCOVERY BY PRODUCING VACCINES UNDER CONTROLLED CONDITIONS SO THAT THEY ARE SUITABLE FOR USE IN HUMAN STUDIES. THIS ENABLES IDRI TO MOVE A VACCINE FROM LATE-STAGE RESEARCH TO EARLY CLINICAL STUDIES. IDRI'S MANUFACTURING SUITE IS "GOOD MANUFACTURING PRACTICE" (GMP)-CERTIFIED AND IS AN INVALUABLE RESOURCE TO IDRI SCIENTISTS AND BIOTECHNOLOGY DEVELOPERS IN THE NON-PROFIT, ACADEMIC, AND FOR-PROFIT SECTORS.
IDRI'S CLINICAL GROUP DESIGNS AND CONDUCTS EARLY-STAGE CLINICAL TRIALS TO TEST THE VACCINE CANDIDATES IDENTIFIED BY IDRI SCIENTISTS OR COLLABORATORS. THROUGH OUR NETWORK OF GLOBAL COLLABORATIONS AND WITH DEEP KNOWLEDGE OF REGULATORY PROCESSES AND PROCEDURES IN THE US AND FOREIGN COUNTRIES, THE CLINICAL TEAM IS ABLE TO LAUNCH CLINICAL TRIALS ALMOST ANYWHERE IN THE WORLD.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Corey Casper CEO | Officer | 40 | $438,281 |
Candice Decaire Chief Strat. Officer & Gen. Couns. | Officer | 40 | $265,625 |
Neil O'connor CFO & COO Thru 12/21 | Officer | 32 | $255,208 |
Anna Marie Beckmann Evp, Product Development | Officer | 40 | $254,688 |
Christopher Fox Senior Vp, Formulations | Officer | 40 | $229,746 |
Linda Hawkins Dir., Quality Assurance & Comp. | Officer | 40 | $183,056 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Shelly Crocker Llc Receivership | 12/30/21 | $907,150 |
Fhi Clinical Inc Clinical Services | 12/30/21 | $1,831,389 |
Cairncross & Hempelmann Legal | 12/30/21 | $573,667 |
Advanced Bioscience Laboratories Inc Clinical Services | 12/30/21 | $544,290 |
Mcnaul Ebel Nawrot & Helgren Pllc Legal | 12/30/21 | $351,231 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $3,304,857 |
| All other contributions, gifts, grants, and similar amounts not included above | $279,582 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $3,584,439 |
| Total Program Service Revenue | $10,969,518 |
| Investment income | $532 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | -$1,720,182 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $13,342,560 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $1,397,163 |
| Compensation of current officers, directors, key employees. | $963,453 |
| Compensation to disqualified persons | $0 |
| Other salaries and wages | $4,084,274 |
| Pension plan accruals and contributions | $140,247 |
| Other employee benefits | $493,608 |
| Payroll taxes | $417,374 |
| Fees for services: Management | $932,550 |
| Fees for services: Legal | $1,135,470 |
| Fees for services: Accounting | $455,503 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $697,002 |
| Advertising and promotion | $940 |
| Office expenses | $80,830 |
| Information technology | $253,641 |
| Royalties | $249,342 |
| Occupancy | $2,335,342 |
| Travel | $2,290 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $4,855 |
| Interest | $112,535 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $1,933,352 |
| Insurance | $139,380 |
| All other expenses | $17,953 |
| Total functional expenses | $19,814,751 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $675,602 |
| Savings and temporary cash investments | $1,587,211 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $3,268,294 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $391,189 |
| Prepaid expenses and deferred charges | $154,808 |
| Net Land, buildings, and equipment | $7,383,389 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $102,604 |
| Other assets | $0 |
| Total assets | $13,563,097 |
| Accounts payable and accrued expenses | $3,996,647 |
| Grants payable | $0 |
| Deferred revenue | $5,341,627 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $919,046 |
| Unsecured mortgages and notes payable | $1,927,711 |
| Other liabilities | $7,788,154 |
| Total liabilities | $19,973,185 |
| Net assets without donor restrictions | -$7,294,061 |
| Net assets with donor restrictions | $883,973 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $13,563,097 |
Grants Awarded
Over the last fiscal year, Infectious Disease Research Institute has awarded $2,903,854 in support to 16 organizations.
| Grant Recipient | Amount |
|---|---|
Charlottesville, VA PURPOSE: RESEARCH | $539,919 |
Charlottesville, VA PURPOSE: RESEARCH | $539,919 |
AMYRIS INC PURPOSE: RESEARCH | $374,856 |
AMYRIS INC PURPOSE: RESEARCH | $374,856 |
St Louis, MO PURPOSE: RESEARCH | $280,230 |
St Louis, MO PURPOSE: RESEARCH | $280,230 |
Grants Recieved
Over the last fiscal year, we have identified 1 grants that Infectious Disease Research Institute has recieved totaling $106.
| Awarding Organization | Amount |
|---|---|
Amazonsmile Foundation Seattle, WA PURPOSE: GENERAL SUPPORT | $106 |
Peer Organizations
| Organization Name | Assets | Revenue |
|---|---|---|
Infectious Disease Research Institute Seattle, WA | $13,563,097 | $13,342,560 |
Let Every Woman Know - Alaska Anchorage, AK | $355,877 | $296,873 |
Dyslexic Advantage Edmonds, WA | $30,084 | $0 |
Asclepius Snakebite Foundation Kirkland, WA | $53,028 | $0 |
World Diagnostics Inc Portland, OR | $55,203 | $0 |
Haleys Heroes Foundation Salem, OR | $418,392 | $373,120 |
Lyman Medical Research Foundation Inc Coeur D Alene, ID | $212 | $0 |
In-Depth Diagnostics Foundation Clyde Hill, WA | $0 | $0 |
Avery Huffman Dipg Foundation Auburn, WA | $57,736 | $0 |
My Jewels Of Hope Poulsbo, WA | $0 | $0 |